Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus- specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis

Blood (2013) 122 (21): 4552.

https://doi.org/10.1182/blood.V122.21.4552.4552

Published: 2013

Journal Articles

Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

Blood (2013) 122 (21): 526.

https://doi.org/10.1182/blood.V122.21.526.526

Published: 2013

Journal Articles

An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission

Blood (2011) 118 (21): 157.

https://doi.org/10.1182/blood.V118.21.157.157

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation of Mantle Cell Lymphoma - Results of the Prodpective Trials OSHO #060 and OSHO #074

William H Krüger, MD, Carsten Hirt, MD, Nadezda Basara, MD, Dietger Niederwieser, MD, Gerhard Behre, Norbert Grobe, Herbert G. Sayer, MD, PhD, Georg Maschmeyer, MD, Thomas Fischer, MD, Michael Kiehl, MD, Christoph Busemann, MD, Gottfried Doelken, MD

Blood (2011) 118 (21): 2014.

https://doi.org/10.1182/blood.V118.21.2014.2014

Published: 2011

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D Schweighofer, MD, Raymonde Busch, Jasmin Renschler, Michael Kiehl, MD, Leopold Balleisen, MD, Michael J Eckart, MD, Anna- Maria Fink, MD, Julia Kilp, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F Eichhorst, MD, Michael Hallek, MD, Clemens- Martin Wendtner, MD, The German CLL Study Group

Blood (2008) 112 (11): 330.

https://doi.org/10.1182/blood.V112.11.330.330

Published: 2008

Journal Articles

Toxicity of Bortezomib: Is There An Influence of Application Rates of Doxorubicin and Dexamethason Administration?a Clinical Monitoring

Wolfram Steinborn, MD, Wolfgang Stein, Sandra Klebe, Michael Kiehl, MD

Blood (2008) 112 (11): 5221.

https://doi.org/10.1182/blood.V112.11.5221.5221

Published: 2008

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D. Schweighofer, MD, Jasmin Renschler, Raymonde Busch, Michael Kiehl, MD, Leopold Balleisen, MD, Michael Eckart, MD, Anna M. Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, Peter Staib, MD, Hartmut Doehner, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 3106.

https://doi.org/10.1182/blood.V110.11.3106.3106

Published: 2007

Journal Articles

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

Nicolaus Kroeger, MD, Brownen Shaw, MD, Simona Iacobelli, PhD, Tatjana Zabelina, MD, Karl Peggs, MD, Avichai Shimoni, MD, Arnon Nagler, MD, Thomas Binder, MD, PhD, Rainer Schwerdtfeger, MD, Michael Kiehl, MD, Herbert G. Sayer, MD, Francis Ayuk, MD, Thomas Eiermann, MD, PhD, David Marks, MD

Blood (2004) 104 (11): 980.

https://doi.org/10.1182/blood.V104.11.980.980

Published: 2004

Journal Articles

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

Nicolaus Kröger, Georgia Schilling, Hermann Einsele, Peter Liebisch, Avichai Shimoni, Arnon Nagler, Jose A. Perez-Simon, Jesus F. San Miguel, Michael Kiehl, Axel Fauser, Rainer Schwerdtfeger, Hannes Wandt, Herbert G. Sayer, Han Myint, Hans Klingemann, Tatjana Zabelina, Judith Dierlamm, Axel Hinke, Axel R. Zander

Blood (2004) 103 (11): 4056–4061.

https://doi.org/10.1182/blood-2003-12-4435

Published: 2004

Journal Articles

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

Nicolaus Kröger, Herbert Gottfried Sayer, Rainer Schwerdtfeger, Michael Kiehl, Arnon Nagler, Helmut Renges, Tatjana Zabelina, Boris Fehse, Francis Ayuk, Georg Wittkowsky, Norbert Schmitz, Axel Rolf Zander

Blood (2002) 100 (12): 3919–3924.

https://doi.org/10.1182/blood-2002-04-1150

Published: 2002

Journal Articles

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

Nicolaus Kröger, Rainer Schwerdtfeger, Michael Kiehl, Herbert Gottfried Sayer, Helmut Renges, Tatjana Zabelina, Boris Fehse, Florian Tögel, Georg Wittkowsky, Rolf Kuse, Axel Rolf Zander

Blood (2002) 100 (3): 755–760.

https://doi.org/10.1182/blood-2002-01-0131

Published: 2002

NARROW

Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus- specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis

An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission

Allogeneic Stem Cell Transplantation of Mantle Cell Lymphoma - Results of the Prodpective Trials OSHO #060 and OSHO #074

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Toxicity of Bortezomib: Is There An Influence of Application Rates of Doxorubicin and Dexamethason Administration?a Clinical Monitoring

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only